The FDA's Drugs@FDA database lists a supplement, dated 24 September, to the new drug application for a premixed daptomycin in 0.9% sodium chloride bag. The entry names the product and application holder but not what the supplement covers.
Supplements are often manufacturing, packaging or labelling changes; the database entry alone does not show a new indication or safety finding. For hospital pharmacies the relevance is to ready-to-use formulations — if the label has changed storage or compatibility details, the updated prescribing information will show it.
The clinical checks for daptomycin are unchanged: weekly creatine kinase, dose adjustment in renal impairment, and remembering it is inactivated by surfactant and cannot treat pneumonia. Availability of this premixed product in India is not established.
- The 24 September entry is a supplement to a premixed daptomycin bag; the change is not specified.
- Check creatine kinase weekly on daptomycin, more often with statins or renal impairment.
- Daptomycin does not treat pneumonia because lung surfactant inactivates it.
- Check the updated FDA label for any storage or compatibility change before assuming one.
Why it matters
Premixed antibiotic labels govern storage and administration on the ward, where small changes cause errors.
Don't overread it
A formulation supplement is not a new indication or a safety warning.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for infectious diseases, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free